Jilin Jian Yisheng Pharmaceutical Co., Ltd. (SHE:002566)
China · Delayed Price · Currency is CNY 6.45
-0.14 (-2.12%)
Aug 4, 2026, 3:04 PM CST
SHE:002566 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,135 | 2,525 | 2,257 | 2,949 | 2,681 | 2,992 | |
Market Cap Growth | -24.56% | 11.88% | -23.46% | 10.00% | -10.40% | 35.74% |
Enterprise Value | 2,080 | 2,540 | 2,289 | 2,979 | 2,869 | 3,226 |
Last Close Price | 6.45 | 7.54 | 6.65 | 8.51 | 7.69 | 8.55 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 64.13 | 87.08 | 43.33 | 31.13 | 32.26 | 31.16 |
Forward PE | - | 49.09 | 49.09 | 49.09 | 49.09 | 49.09 |
PS Ratio | 3.24 | 3.94 | 3.38 | 3.45 | 3.23 | 3.41 |
PB Ratio | 0.91 | 1.08 | 0.97 | 1.26 | 1.19 | 1.36 |
P/TBV Ratio | 1.00 | 1.19 | 1.06 | 1.39 | 1.32 | 1.53 |
P/FCF Ratio | 21.16 | 29.67 | 52.49 | 17.01 | 25.66 | 27.69 |
P/OCF Ratio | 19.71 | 25.57 | 38.29 | 14.10 | 18.38 | 13.91 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.15 | 3.97 | 3.42 | 3.49 | 3.46 | 3.67 |
EV/EBITDA Ratio | 37.43 | 41.88 | 22.96 | 19.59 | 22.27 | 20.91 |
EV/EBIT Ratio | 149.22 | 114.64 | 40.21 | 27.88 | 32.33 | 28.30 |
EV/FCF Ratio | 20.62 | 29.85 | 53.23 | 17.18 | 27.46 | 29.86 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.21 | 0.19 | 0.19 | 0.20 | 0.20 | 0.19 |
Debt / EBITDA Ratio | 8.68 | 6.88 | 4.32 | 3.06 | 3.34 | 2.64 |
Debt / FCF Ratio | 4.78 | 5.24 | 10.46 | 2.75 | 4.25 | 3.84 |
Net Debt / Equity Ratio | -0.06 | -0.05 | -0.04 | -0.05 | 0.02 | 0.04 |
Net Debt / EBITDA Ratio | -2.97 | -2.06 | -0.82 | -0.75 | 0.31 | 0.62 |
Net Debt / FCF Ratio | -1.51 | -1.47 | -1.90 | -0.66 | 0.39 | 0.88 |
Asset Turnover | 0.22 | 0.22 | 0.22 | 0.28 | 0.28 | 0.31 |
Inventory Turnover | 0.11 | 0.11 | 0.11 | 0.14 | 0.14 | 0.14 |
Quick Ratio | 2.07 | 2.09 | 2.02 | 1.36 | 1.17 | 1.15 |
Current Ratio | 5.86 | 6.24 | 6.49 | 4.12 | 3.92 | 4.16 |
Return on Equity (ROE) | 1.41% | 1.24% | 2.17% | 4.20% | 3.97% | 4.83% |
Return on Assets (ROA) | 0.29% | 0.47% | 1.18% | 2.22% | 1.90% | 2.52% |
Return on Invested Capital (ROIC) | 0.61% | 0.96% | 2.17% | 4.08% | 3.38% | 4.25% |
Return on Capital Employed (ROCE) | 0.50% | 0.90% | 2.20% | 4.30% | 3.70% | 4.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.56% | 1.15% | 2.31% | 3.21% | 3.10% | 3.21% |
FCF Yield | 4.73% | 3.37% | 1.91% | 5.88% | 3.90% | 3.61% |
Dividend Yield | 1.21% | 1.06% | 1.50% | 1.76% | 0.65% | 0.35% |
Payout Ratio | 135.25% | 157.27% | 118.33% | 31.52% | - | 24.29% |
Buyback Yield / Dilution | 0.03% | -0.04% | 0.03% | -0.02% | 0.02% | -0.01% |
Total Shareholder Return | 1.26% | 1.02% | 1.53% | 1.74% | 0.67% | 0.34% |